Günther A, Bleyl H, Seeger W
Department of Internal Medicine, Justus Liebig University, Giessen, Germany.
Am J Physiol. 1993 Aug;265(2 Pt 1):L186-92. doi: 10.1152/ajplung.1993.265.2.L186.
Fibrinogen (Fbg) leakage and intra-alveolar fibrin accumulation are commonly noticed in adult respiratory distress syndrome and interstitial lung diseases. Activation of the extrinsic coagulation pathway and elevation of antiplasmin- and plasminogen-activator inhibitor levels are assumed to favor alveolar clot formation and to inhibit fibrinolysis under these conditions. We investigated the influence of synthetic surfactants on the plasmic cleavage of fibrinogen in vitro. Fibrinogenolysis was quantified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis with densitometric evaluation and fragment E enzyme-linked immunosorbent assay. A synthetic phospholipid mixture (PLM) (dipalmitoyl-DL-alpha-phosphatidylcholine:L-alpha-phosphatidyl-DL-gly cer ol: palmitic acid 68.5:22.5:9) caused a dose-dependent inhibition of fibrinogenolysis in a concentration range between 0.1 and 2 mg/ml. This inhibitory capacity was markedly amplified upon reconstitution of PLM with natural and recombinant surfactant protein (SP)-C as well as natural SP-B. Natural SP-A and recombinant SP-A were far less effective in this respect. In the absence of phospholipids, the hydrophobic apoproteins revealed only moderate plasmin inhibitory capacity (recombinant SP-C > natural SP-C and SP-B). Natural calf lung surfactant extract displayed comparable inhibitory capacity on plasmic Fbg cleavage as PLM. We conclude that hydrophobic surfactant material may suppress plasmin activity and thus may contribute to the finding of delayed alveolar fibrin clearance in inflammatory lung diseases with Fbg leakage.
在成人呼吸窘迫综合征和间质性肺疾病中,常见纤维蛋白原(Fbg)渗漏和肺泡内纤维蛋白积聚。在这些情况下,外源性凝血途径的激活以及抗纤溶酶和纤溶酶原激活物抑制剂水平的升高被认为有利于肺泡内血栓形成并抑制纤维蛋白溶解。我们在体外研究了合成表面活性剂对纤维蛋白原血浆裂解的影响。通过十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳结合光密度评估和片段E酶联免疫吸附测定对纤维蛋白原溶解进行定量。一种合成磷脂混合物(PLM)(二棕榈酰 - DL-α - 磷脂酰胆碱:L-α - 磷脂酰 - DL - 甘油:棕榈酸68.5:22.5:9)在0.1至2 mg/ml的浓度范围内引起剂量依赖性的纤维蛋白原溶解抑制。在用天然和重组表面活性蛋白(SP)-C以及天然SP - B重构PLM后,这种抑制能力明显增强。天然SP - A和重组SP - A在这方面的效果要差得多。在没有磷脂的情况下,疏水载脂蛋白仅显示出中等程度的纤溶酶抑制能力(重组SP - C>天然SP - C和SP - B)。天然小牛肺表面活性剂提取物对血浆Fbg裂解的抑制能力与PLM相当。我们得出结论,疏水表面活性物质可能抑制纤溶酶活性,因此可能导致在伴有Fbg渗漏的炎症性肺疾病中出现肺泡纤维蛋白清除延迟的现象。